肿瘤药学
腫瘤藥學
종류약학
ANTI-TUMOR PHARMACY
2013年
2期
130-132
,共3页
陈意标%张汉雄%张坚%俞海东%邓国明%洪珊%薛祥兴
陳意標%張漢雄%張堅%俞海東%鄧國明%洪珊%薛祥興
진의표%장한웅%장견%유해동%산국명%홍산%설상흥
食管癌%纵隔淋巴结转移%三维适形放疗%小野
食管癌%縱隔淋巴結轉移%三維適形放療%小野
식관암%종격림파결전이%삼유괄형방료%소야
Esophageal carcinoma%Mediastinal lymph node metastasis%Three dimensional conformal radiation therapy%Small field
目的探讨食管癌根治术后纵隔淋巴结转移三维适形放射治疗的临床疗效,分析治疗失败的原因及局部小野放疗的可行性.方法回顾性分析45例食管癌根治术后纵隔淋巴结转移的患者,采用三维适形小野放射治疗,GTV 处方剂量64 Gy,CTV 处方剂量50 Gy,常规分割;GTV 外放1.0~1.5 cm 为 CTV,其他无转移部位不予预防性照射.放疗后3个月行 CT 检查,按 WHO 实体瘤疗效评价标准评估临床疗效.结果治疗的总有效率为73.3%,完全缓解率为33.3%,中位生存时间为16.7月;治疗过程中无明显毒副反应.结论对于食管癌根治术后纵隔淋巴结转移的患者,三维适形放射治疗是较好的治疗手段.
目的探討食管癌根治術後縱隔淋巴結轉移三維適形放射治療的臨床療效,分析治療失敗的原因及跼部小野放療的可行性.方法迴顧性分析45例食管癌根治術後縱隔淋巴結轉移的患者,採用三維適形小野放射治療,GTV 處方劑量64 Gy,CTV 處方劑量50 Gy,常規分割;GTV 外放1.0~1.5 cm 為 CTV,其他無轉移部位不予預防性照射.放療後3箇月行 CT 檢查,按 WHO 實體瘤療效評價標準評估臨床療效.結果治療的總有效率為73.3%,完全緩解率為33.3%,中位生存時間為16.7月;治療過程中無明顯毒副反應.結論對于食管癌根治術後縱隔淋巴結轉移的患者,三維適形放射治療是較好的治療手段.
목적탐토식관암근치술후종격림파결전이삼유괄형방사치료적림상료효,분석치료실패적원인급국부소야방료적가행성.방법회고성분석45례식관암근치술후종격림파결전이적환자,채용삼유괄형소야방사치료,GTV 처방제량64 Gy,CTV 처방제량50 Gy,상규분할;GTV 외방1.0~1.5 cm 위 CTV,기타무전이부위불여예방성조사.방료후3개월행 CT 검사,안 WHO 실체류료효평개표준평고림상료효.결과치료적총유효솔위73.3%,완전완해솔위33.3%,중위생존시간위16.7월;치료과정중무명현독부반응.결론대우식관암근치술후종격림파결전이적환자,삼유괄형방사치료시교호적치료수단.
@@@@Objective To investigate the significance and curative effect of three dimensional conformal radiation therapy (3D-CRT) in mediastinal lymph node metastasis after radical resection of esophageal carcinoma. Methods A retrospec-tive analysis was done by 45 patients with mediastinal lymph node metastasis after radical resection of esophageal carcinoma. They were treated by conventional fractionated SF-3DCRT, the GTV (gross tumor volume) prescription dose is 64 Gy and the CTV (clinical target volume) prescription dose is 50 Gy, CTV is 1~1.5 cm Outside the scope of GTV. No prophylactic irradiation in the other site which is not metastasis. Results CT examinations were taken after 3 months’radiotherapy. Ac-cording to RECIST(Response Evaluation Criteria in Solid Tumors), the total effective rate is 73.3%, the complete remission rate is 33.3%, the median survival time is 16.7 months, toxicity and side effect are not obvious. Conclusion 3DCRT is rec-ommended for the patients with Mediastinal Lymph Node Metastasis after Radical Resection of Esophageal Carcinoma.